SPAC lawsuits push banks, CIBC to strengthen capital markets compliance

Rising SPAC litigation tightens compliance focus for banks' capital markets teams

Global and Canadian banks are sharpening internal controls as shareholder litigation around special purpose acquisition companies (SPACs) increasingly moves through Delaware courts, a trend that bears direct relevance to Canadian Imperial Bank of Commerce’s (CIBC) capital markets and underwriting operations. A recent preliminary class certification and proposed $7.25 million cash settlement in a consolidated suit against CM Life Sciences III highlights persistent legal exposure tied to disclosure and proxy processes in SPAC transactions. Banks that advise, underwrite or provide financing for SPACs face heightened scrutiny over due diligence, deal marketing and the accuracy of public statements that can form the basis of post‑dealmaker litigation.

Investment banks, including CIBC’s corporate and investment banking teams, are adapting by refining disclosure checks, expanding legal sign‑offs and tightening client engagement protocols to reduce potential secondary liability. The CM Life Sciences III case, heard in the Delaware Court of Chancery, underscores how courts may certify broad classes and pursue recoveries where plaintiffs allege misstatements or omissions around redemption deadlines and shareholder communications — areas where banks often assist in structuring and communicating transactions. Increased litigation activity prompts firms to invest in pre‑deal legal reviews and post‑deal monitoring to limit reputational and regulatory fallout.

The settlement environment also pushes transactional teams to weigh litigation financing and indemnity structures more carefully when negotiating deal agreements. For CIBC, which competes for advisory mandates in the North American SPAC market, these developments encourage more conservative representations and warranties, clearer allocation of post‑closing responsibilities, and more explicit ticketing of legal risk in fee and holdback arrangements. The net effect is a modest shift toward greater legal involvement in early deal stages and an operational emphasis on document trail and investor communications.

Delaware court action and settlement specifics

In the case Milana Nemeth et al. v. Casdin et al. (C.A. No. 2024‑1268‑PAF), the Court of Chancery preliminarily certifies a class of CM Life Sciences III Class A shareholders who held stock immediately after the 5:00 p.m. ET redemption deadline on Dec. 14, 2021, and the parties agree to a proposed $7,250,000 cash settlement dated Jan. 5, 2026. A fairness hearing is scheduled for April 21, 2026 before Judge Paul A. Fioravanti in Wilmington, Delaware; notices and the stipulation are posted at www.cmlsiiistockholdersettlement.com, and affected holders may object, appear through counsel or seek exclusion per the Court‑approved procedures.